ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion

MT Newswires Live06-28 21:13

ARS Pharmaceuticals (SPRY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a "positive opinion" on the company's application for marketing authorization for its adrenaline nasal spray, EURneffy, to treat allergic reactions.

The committee's recommendation will be submitted to the European Commission for the formal marketing authorization process, expected in Q3, ARS said.

If approved, EURneffy will be made available in Europe in Q4, according to ARS.

In the US, the company said the Food and Drug Administration is expected to decide by Oct. 2 on its new drug application for neffy, the company said.

The company's shares were 5.6% higher in recent premarket activity.

Price: 8.50, Change: +0.45, Percent Change: +5.59

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446507719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-28 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446507719","market":"nz","top_or_hot":-1,"title":"ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion","media":"MT Newswires Live","content":"<html><body><p> ARS Pharmaceuticals (SPRY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a \"positive opinion\" on the company's application for marketing authorization for its adrenaline nasal spray, EURneffy, to treat allergic reactions.</p><p>The committee's recommendation will be submitted to the European Commission for the formal marketing authorization process, expected in Q3, ARS said.</p><p>If approved, EURneffy will be made available in Europe in Q4, according to ARS.</p><p>In the US, the company said the Food and Drug Administration is expected to decide by Oct. 2 on its new drug application for neffy, the company said.</p><p>The company's shares were 5.6% higher in recent premarket activity.</p><p>Price: 8.50, Change: +0.45, Percent Change: +5.59</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-28 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ARS Pharmaceuticals (SPRY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a \"positive opinion\" on the company's application for marketing ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2446507719","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446507719","pubTimestamp":1719580433,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ARS Pharmaceuticals  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a \"positive opinion\" on the company's application for marketing authorization for its adrenaline nasal spray, EURneffy, to treat allergic reactions.The committee's recommendation will be submitted to the European Commission for the formal marketing authorization process, expected in Q3, ARS said.If approved, EURneffy will be made available in Europe in Q4, according to ARS.In the US, the company said the Food and Drug Administration is expected to decide by Oct. 2 on its new drug application for neffy, the company said.The company's shares were 5.6% higher in recent premarket activity.Price: 8.50, Change: +0.45, Percent Change: +5.59","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRY":"ARS PHARMACEUTICALS INC"},"translate_title":"ARS Pharmaceuticals的肾上腺素鼻喷雾剂获得EMA委员会的积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"ARS Pharmaceuticals (SPRY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a \"positive opinion\" on the company's application for marketing authorization for its adrenaline nasal spray, EURneffy, to treat allergic reactions.The committee's recommendation will be submitted to the European Commission for the formal marketing authorization process, expected in Q3, ARS said.If approved, EURneffy will be made available in Europe in Q4, according to ARS.In the US, the company said the Food and Drug Administration is expected to decide by Oct. 2 on its new drug application for neffy, the company said.The company's shares were 5.6% higher in recent premarket activity.Price: 8.50, Change: +0.45, Percent Change: +5.59","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446507719"}